Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome‐positive Leukemia

[1]  M. Konopleva,et al.  Hyper‐CVAD plus ponatinib versus hyper‐CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia: A propensity score analysis , 2016, Cancer.

[2]  G. Garcia-Manero,et al.  Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. , 2016, Blood.

[3]  Xuelin Huang,et al.  Minimal residual disease assessed by multi‐parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia , 2016, British journal of haematology.

[4]  H. Dombret,et al.  Long-Term Outcomes after Blinatumomab Treatment: Follow-up of a Phase 2 Study in Patients (Pts) with Minimal Residual Disease (MRD) Positive B-Cell Precursor Acute Lymphoblastic Leukemia (ALL) , 2015 .

[5]  H. Dombret,et al.  Complete Molecular and Hematologic Response in Adult Patients with Relapsed/Refractory (R/R) Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia (ALL) Following Treatment with Blinatumomab: Results from a Phase 2 Single-Arm, Multicenter Study (ALCANTARA) , 2015 .

[6]  H. Kantarjian,et al.  Treatment with Anti-CD19 BiTE® Blinatumomab in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (r/r ALL) Post-Allogeneic Hematopoietic Stem Cell Transplantation , 2015 .

[7]  Z. Estrov,et al.  Long‐term follow‐up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia , 2015, Cancer.

[8]  M. Konopleva,et al.  Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. , 2015, The Lancet. Oncology.

[9]  H. Kantarjian,et al.  Monoclonal antibodies in acute lymphoblastic leukemia. , 2015, Blood.

[10]  R. Larson,et al.  Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. , 2015, The Lancet. Oncology.

[11]  Martin C. Müller,et al.  Long-Term Follow-up of Ponatinib Efficacy and Safety in the Phase 2 PACE Trial , 2014 .

[12]  A. Ganser,et al.  BLAST: A Confirmatory, Single-Arm, Phase 2 Study of Blinatumomab, a Bispecific T-Cell Engager (BiTE®) Antibody Construct, in Patients with Minimal Residual Disease B-Precursor Acute Lymphoblastic Leukemia (ALL) , 2014 .

[13]  J. Esteve,et al.  Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  H. Einsele,et al.  Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. , 2012, Blood.

[15]  E. Thiel,et al.  Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. , 2012, Blood.

[16]  Hermann Einsele,et al.  Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  H. Kantarjian,et al.  Kinase domain point mutations in Philadelphia chromosome‐positive acute lymphoblastic leukemia emerge after therapy with BCR‐ABL kinase inhibitors , 2008, Cancer.

[18]  J. Radich,et al.  End points to establish the efficacy of new agents in the treatment of acute leukemia. , 2007, Blood.

[19]  Steven M Kornblau,et al.  Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. , 2004, Blood.

[20]  L. Medeiros,et al.  TaqMan RT-PCR assay coupled with capillary electrophoresis for quantification and identification of bcr-abl transcript type , 2004, Modern Pathology.

[21]  M. Mack,et al.  A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. , 1995, Proceedings of the National Academy of Sciences of the United States of America.